TABLE 3.
3TC and ZDV resistance-associated mutations and phenotypic resistance in mutants with site-directed mutations
| Mutant | 3TC resistance profile
|
AZT resistance profile
|
||||
|---|---|---|---|---|---|---|
| Mutation(s) | Fold resistancea | nb | Mutations | Fold resistance | n | |
| SDM05 | 4 (0.3)c | 4 | 41L, 210W,211K,214F,215Y | 64 (15.0) | 5 | |
| SDM18 | 2 (0.6) | 3 | 41L, 67N,210W,211K,214F,215Y | 45 (13.4) | 3 | |
| SDM19 | 4 (0.7) | 3 | 41L, 67N,69D,210W,211K,214F,215Y | 46 (18.2) | 2 | |
| SDM28 | 44D | 1 (0.1) | 6 | 2 (0.3) | 6 | |
| SDM31 | 44D | 22 (2.5) | 5 | 41L, 67N,210W,211K,214F,215Y | 48 (11.8) | 4 |
| SDM32 | 44D | 8 (2.2) | 4 | 41L, 67N,69D,210W,211K,214F,215Y | 49 (5.9) | 6 |
| SDM29 | 118I | 2 (0.2) | 6 | 2 (0.4) | 6 | |
| SDM33 | 118I | 7 (1.0) | 5 | 41L, 67N,210W,211K,214F,215Y | 49 (8.0) | 6 |
| SDM34 | 118I | 32 (3.9) | 5 | 41L, 67N,69D,210W,211K,214F,215Y | 34 (14.4) | 5 |
| SDM30 | 44D,118I | 3 (0.3) | 6 | 1 (0.4) | 6 | |
| SDM35 | 44D,118I | 14 (1.4) | 6 | 41L, 67N,210W,211K,214F,215Y | 49 (9.6) | 5 |
| SDM36 | 44D,118I | 15 (2.1) | 6 | 41L, 67N,69D,210W,211K,214F,215Y | 49 (10.6) | 5 |
| SDM22 | 184V | 78 (16.3) | 5 | 41L,210W,211K,214F,215Y | 7 (0.9) | 5 |
| SDM23 | 184V | 82 (13.6) | 6 | 2 (0.5) | 6 | |
| SDM24 | 184V | 85 (14.2) | 6 | 69S-S-S, 210W,211K,214F,215Y | 27 (16.2) | 5 |
| SDM26 | 184V | 72 (13.8) | 5 | 41L, 67N,210W,211K,214F,215Y | 25 (1.4) | 5 |
| SDM38 | 184V,44D,118I | 82 (13.5) | 6 | 41L, 67N,210W,211K,214F,215Y | 20 (4.1) | 6 |
| SDM39 | 184V,44D,118I | 84 (13.9) | 6 | 41L, 67N,69D,210W,211K,214F,215Y | 21 (5.3) | 5 |
a
Fold increase in the mean IC50 of the drug relative to the mean IC50 of the same drug for a wild-type reference laboratory HIV-1 strain.
b
n, number of replicate tests run for each phenotypic drug resistance determination.
c
Standard errors are indicated in parentheses.